Orgenesis Inc. Book value per Share

Book value per Share of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.

Highlights and Quick Summary

  • Book value per Share for the quarter ending September 29, 2021 was 1.78 (a -15.74% decrease compared to previous quarter)
  • Year-over-year quarterly Book value per Share decreased by -18.36%
  • Annual Book value per Share for 2020 was 2.47 (a 616.26% increase from previous year)
  • Annual Book value per Share for 2019 was 0.34 (a -83.76% decrease from previous year)
  • Annual Book value per Share for 2018 was 2.12 (a -1.04% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of Orgenesis Inc.

Most recent Book value per Shareof ORGS including historical data for past 10 years.

Interactive Chart of Book value per Share of Orgenesis Inc.

Orgenesis Inc. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 1.78 2.11 2.25
2020 2.18 3.92 4.11 5.04 2.47
2019 0.38 0.69 1.05 1.37 0.34
2018 0.0 2.09 1.96 1.81 2.12
2017 0.0 1.09 1.03 0.0 1.46
2016 0.0 0.0 0.0 0.0 0.0 1.47
2015 0.0 -1.39
2014 0.0 -0.66
2013 0.0 -0.48
2012 0.0 -0.06
2011 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.